9.07
price down icon0.55%   -0.05
after-market Dopo l'orario di chiusura: 9.06 -0.010 -0.11%
loading
Precedente Chiudi:
$9.12
Aprire:
$9.03
Volume 24 ore:
119.91K
Relative Volume:
0.63
Capitalizzazione di mercato:
$3.21B
Reddito:
$391.87M
Utile/perdita netta:
$-441.45M
Rapporto P/E:
-4.9027
EPS:
-1.85
Flusso di cassa netto:
$-301.21M
1 W Prestazione:
-1.63%
1M Prestazione:
-20.72%
6M Prestazione:
-31.44%
1 anno Prestazione:
-26.62%
Intervallo 1D:
Value
$9.03
$9.24
Intervallo di 1 settimana:
Value
$9.03
$9.505
Portata 52W:
Value
$7.35
$13.70

Alvotech Stock (ALVO) Company Profile

Name
Nome
Alvotech
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,032
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
ALVO's Discussions on Twitter

Confronta ALVO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ALVO
Alvotech
9.07 3.21B 391.87M -441.45M -301.21M -1.85
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
14.60 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.19 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.35 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.37 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.64 20.17B 16.54B -1.64B 749.00M -1.45

Alvotech Stock (ALVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-14 Iniziato UBS Buy
2024-01-29 Aggiornamento Barclays Equal Weight → Overweight
2023-10-20 Aggiornamento Citigroup Sell → Neutral
2023-09-21 Iniziato Barclays Equal Weight
2022-09-07 Iniziato Morgan Stanley Equal-Weight
2022-09-06 Downgrade Citigroup Buy → Sell
2022-07-26 Iniziato Citigroup Buy
Mostra tutto

Alvotech Borsa (ALVO) Ultime notizie

pulisher
Jun 19, 2025

Day 8 of Loss Streak for Alvotech Stock with -15% Return (vs. -32% YTD) [6/18/2025] - Trefis

Jun 19, 2025
pulisher
Jun 18, 2025

Alvotech and Dr. Reddy’s Partner to Develop Biosimilar of Merck’s Keytruda for Global Cancer Treatment - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab - geneonline.com

Jun 18, 2025
pulisher
Jun 17, 2025

Short Interest in Alvotech (NASDAQ:ALVO) Grows By 75.2% - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan - Center for Biosimilars

Jun 17, 2025
pulisher
Jun 17, 2025

Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Keytruda Cancer Drug - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar - Drug Store News

Jun 17, 2025
pulisher
Jun 16, 2025

Alvotech (NASDAQ:ALVO) Trading Down 3.3%Should You Sell? - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Trims Position in Alvotech (NASDAQ:ALVO) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda - MSN

Jun 14, 2025
pulisher
Jun 12, 2025

Linklaters Advises Syndicate on Alvotech’s SEK 750 Million Private Placement - Global Legal Chronicle

Jun 12, 2025
pulisher
Jun 12, 2025

Alvotech Completes Private Placement to Boost Shareholder Base - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Pembrolizumab Used in Cancer Treatment - geneonline.com

Jun 12, 2025
pulisher
Jun 11, 2025

Alvotech completes private placement with 40 institutional investors By Investing.com - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech Completes Successful Private Placement with Global Institutional Investors - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

REG-Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - TradingView

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech Attracts 40 New Global Investors in Strategic Private Placement, 80% First-Time Buyers - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Alvotech Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 08 - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Alvotech Partners with Dr. Reddy’s for Keytruda Biosimilar Development - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

Alvotech, Advanz Pharma expand biosimilar deal in Europe - Drug Store News

Jun 09, 2025
pulisher
Jun 08, 2025

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment - MSN

Jun 08, 2025
pulisher
Jun 08, 2025

Dr Reddy’s–Alvotech deal: Why investors are bullish - MSN

Jun 08, 2025
pulisher
Jun 07, 2025

Dr Reddys Lab gains on global biosimilar deal with Alvotech - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Alvotech (NASDAQ:ALVO) Stock Price Down 4.8%What's Next? - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab) - BioSpectrum Asia

Jun 07, 2025
pulisher
Jun 07, 2025

Alvotech and Dr. Reddy’s Join Forces to Develop Biosimilar | - Chemical Industry Digest

Jun 07, 2025
pulisher
Jun 07, 2025

Alvotech (ALVO) Partners with Dr. Reddy's for Keytruda Biosimila - GuruFocus

Jun 07, 2025
pulisher
Jun 07, 2025

Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Alvotech and Dr. Reddy’s partner for Keytruda biosimilar - Pharmaceutical Business review -

Jun 06, 2025
pulisher
Jun 06, 2025

Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Alvotech and Dr. Reddy’s to co-develop biosimilar to Keytruda - World Pharmaceutical Frontiers

Jun 06, 2025
pulisher
Jun 06, 2025

Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with Alvotech - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Alvotech to Participate in Goldman Sachs 46th Global Healthcare Conference in Miami - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - Yahoo

Jun 06, 2025
pulisher
Jun 05, 2025

Alvotech (ALVO) Trading Down 4.8% on Jun 4 - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Alvotech Completes SEK 750 Million Private Placement to Boost R&D and Market Position - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga

Jun 05, 2025

Alvotech Azioni (ALVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$14.43
price up icon 1.05%
$9.18
price up icon 2.80%
$128.00
price up icon 1.84%
$290.91
price up icon 1.24%
drug_manufacturers_specialty_generic RDY
$14.94
price down icon 0.60%
$16.64
price down icon 0.72%
Capitalizzazione:     |  Volume (24 ore):